Rznomics Inc. (Ticker: 476830 KS) is a South Korean biotechnology company specializing in RNA-based gene therapeutics. The company utilizes a proprietary RNA trans-splicing enzyme platform to develop treatments for oncology, genetic disorders, and degenerative diseases, alongside a circular RNA platform for next-generation bio-pharmaceuticals.

Rznomics plans to list on the KOSDAQ on December 18, 2025. The company is offering 2.06 million shares at a fixed price of KRW 22,500, raising KRW 46.35 billion ($33 million). At this pricing, the company anticipates a market capitalization of KRW 309.83 billion ($221 million). The offering consists entirely of primary shares (100% new shares). Reportedly, the company intends to use the proceeds to accelerate clinical development of its pipeline and enhance its platform technologies. Samsung Securities and NH Investment & Securities are acting as joint managers for the offering.